The invention relates to an anhydrous crystalline form of (1,1-dioxo-hexahydro-1lambda*6*- thiopyran-4-yl)-{(S)-3-[1-(6-methoxy-5-methyl-pyridin-3-yl)-2,3-dihydro-1H-pyrido[3,4- b][1,4]oxazin-7-yloxy]-pyrrolidin-1-yl}-methanone pharmaceutical compositions and combinations including these forms as well as to methods of using these forms, including their pharmaceutical compositions and combinations for the treatment of diseases.La présente invention concerne une forme cristalline anhydre de (1,1-dioxo-hexahydro-1lambda*6*- thiopyran-4-yl)-{(S)-3-[1-(6-méthoxy-5-méthyl-pyridin-3-yl)-2,3-dihydro-1H-pyrido[3,4-b][1,4]oxazin-7-yloxy]-pyrrolidin-1-yl}-méthanone des compositions et des combinaisons pharmaceutiques incluant ces formes ainsi que des procédés dutilisation de ces formes, incluant leurs compositions et combinaisons pharmaceutiques pour le traitement de maladies.
